New Study Examines Effectiveness of Colorectal Cancer Screening Tests

	Tweet

New findings from a Decision Analysis for the US Preventative Services Task Force (USPSTF) suggest that routine colorectal cancer screenings can be stopped in patients over the age of 75. The results are based on patients who began screenings at age 50 and have had consistently negative screenings up to the age of 75. Lead author Ann Graham Zauber, PhD, Associate Attending Biostatistician in the Department of Epidemiology and Biostatistics at Memorial Sloan-Kettering Cancer Center and her colleagues’ findings are published in the October 7, 2008 online edition of Annals of Internal Medicine and will appear in a forthcoming issue.

“To date there has been no age to stop colorectal cancer screening. Our results suggest that there is little gain in life expectancy in continuing colorectal cancer screening after age 75, for those who have had repeated negative screening examinations since the age of 50. People who have had adenomas or colorectal cancer should continue surveillance after age 75,” said Dr. Zauber, who added that “our findings also suggest that the more sensitive fecal occult blood tests can provide comparable life years saved to screening colonoscopy provided high adherence to these screening tests.”

In July 2002, the USPSTF concluded that there was enough evidence to recommend strongly that all average risk adults 50 years of age and older be offered colorectal cancer screening. However, the logistics of screening such as type of screening test, screening intervals, and age to stop screening were not evaluated in terms of the balance of benefits and potential harms. In updating its recommendations for 2008, the USPSTF requested a decision analysis to project expected outcomes of various colorectal cancer screening strategies to inform its update of the recommendations for colorectal cancer screening.

“Our objective was to assess life years gained and colonoscopy requirements for colorectal cancer screening strategies and identify a set of recommendable screening strategies,” said Dr. Zauber.

These decision analysis findings support colorectal cancer screening with annual screening with sensitive Fecal Occult Blood Test (FOBT), ten yearly colonoscopies, or five yearly sigmoidoscopies with a mid-interval sensitive FOBT from ages 50 to 75.

This is the first time that the USPSTF has incorporated a decision analysis to inform its recommendations. Previously the Task Force has used an extensive structured literature review. This time, the USPSTF has both the evidence review of published work and this decision analysis, which considered 145 different strategies (90 single-test strategies, 54 combination-test strategies, and one no screening-strategy) on age to begin, age to stop, and intervals of testing for guaiac FOBT (lower and higher sensitivity test), fecal immunochemical test, and flexible sigmoidoscopy alone and with a sensitive FOBT. Dr. Zauber and colleagues translated the best evidence from randomized trials into structured and comparable outcomes of life years saved relative to use of colonoscopy resources. This work represents the transition from evidence-based to evidence-informed recommendations.

“This excellent decision analysis by Dr. Zauber and colleagues confirms the validity of colorectal cancer screening in men and women ages 50 to 75, which will provide the greatest benefit with saving of resources. Unfortunately the majority of Americans in this age range do not get screened at all, resulting in tragic consequences for them and their families. There is no reason why 50,000 people should die of this disease in America each year,” added Dr. Sidney Winawer, the Paul Sherlock Chair in Medicine in the Gastroenterology and Nutrition Service at Memorial Sloan-Kettering Cancer Center.

This research is joint work of Memorial Sloan-Kettering Cancer Center with Erasmus MC of Rotterdam, the Netherlands, the University of Minnesota, and Massachusetts General Hospital as part of the Cancer Intervention and Surveillance Modeling Network (CISNET) of NCI and is an example of comparative modeling with independently developed microsimulation models. This study was funded by grants from the National Cancer Institute and the Agency for HealthCare Research and Quality.

Memorial Sloan-Kettering Cancer Center is the world’s oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose, and treat cancer. Our specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide.

Source: Memorial Sloan-Kettering Cancer Center

RELATED STORIES:
Omega 3s may help cut colon cancer risk   Colon cancer risk in women does not seem to be reduced by physical activity   The cellular root of colorectal cancers?   Colorectal cancer attitudes vary by ethnicity   Colon Cancer, Its Link To Diabetes, And Dietary Pattern   Program Identifies Families at High Risk for Colorectal Cancer   Obesity linked to poor colon cancer prognosis   Magnesium may curb colon cancer risk in women   Smoking-related colorectal cancer in older women is associated with molecularly-defined DNA changes   Not all doctors follow cancer screening guidelines   Compounds in mate tea induce death in colon cancer cells   Protein found in heart may be target for colon cancer therapies   Lifestyle Changes Would Lead to Sharp Drop in Colorectal Cancers   How to Lower Costs, Waiting Times for Colonoscopies   Most Adults Don’t Realize Activity Lowers Colon Cancer Risk   Hispanics live in areas with limited capacity for colorectal cancer screening   Cancer detected earlier, faster, with new medical imaging, Stanford study finds   Targeted Therapies Showing Great Promise Against Colorectal Cancer   Chemical changes may help detect colon cancer early   Different type of colon cancer vaccine reduces disease spread, Jefferson scientists show   PET scans lead to treatment changes in majority of colorectal cancer patients   Identified a cause of resistance to colon cancer treatment

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]